List of Figures
Figure 1-1: Blood Comparison of a Healthy Person & Leukemia Patient
Figure 1-2: Major Characteristics of Leukemia Subtypes
Figure 1-3: Comparison for Subtypes of Leukemia by Average Age of Diagnosis & 5-Year Survival Percentage
Figure 1-4: Contributors to the History of Leukemia
Figure 2-1: Available Cancer Treatments for Leukemia in the Market
Figure 2-2: Global – Leukemia Death Statistics, 2018
Figure 3-1: Cancer Types vs. Leukemia Cancer Treatments
Figure 4-1: Treanda – Total Sales (US$ Million), 2016 - 2019
Figure 4-2: Tasigna – Total Sales (US$ Million), 2016 - 2019
Figure 4-3: Global – Total vs. Active, not Recruiting Chemotherapy Clinical Trials, 2020
Figure 4-4: Mechanism of Action of Chemotherapeutic Drugs on Leukemia Cells
Figure 5-1: Global – Kymriah Total Sales (US$ Million), 2017 - 2019
Figure 5-2: Global – Total vs. Active, not Recruiting Immunotherapy Clinical Trials for Leukemia, 2020
Figure 5-3: Outcomes Anticipated by the Arrival of Immunotherapy Treatment for Leukemic Patients
Figure 5-4: Mechanism of Action of Immunotherapy on Leukemia Cells
Figure 6-1: Properties of Small Molecule Cancer Drugs
Figure 6-2: Global – Gleevec Total Sales (US$ Million), 2018 & 2019
Figure 6-3: Mechanism of Action of Small Molecule Cancer Drugs on Leukemia Cells
Figure 7-1: Global – Total vs. Active, not Recruiting Bone Marrow Transplantation Clinical Trials, 2020
Figure 7-2: Global –Bone Marrow Transplantation Market (US$ Billion), 2018 - 2025
Figure 7-3: Mechanism of Action of Bone Marrow Transplantation in Leukemia Patients
Figure 8-1: Radiation Therapy – Clinical Trials for Leukemia Subtypes, 2020
Figure 8-2: Mechanism of Action of Radiation Therapy for Leukemia Patients
Figure 11-1: Global - Leukemia Market (US$ Billion), 2019 - 2025
Figure 12-1: US – Leukemia Statistics, 2018
Figure 12-2: US – Total vs. Active Leukemia Clinical Trials, 2020
Figure 12-3: US - Rising Parameters for Leukemia Therapeutics Market
Figure 12-4: Europe – Leukemia Statistics, 2018
Figure 12-5: Europe – Total Leukemia Clinical Trials, 2020
Figure 12-6: Europe - Important Parameters for Leukemia Market Growth
Figure 12-7: Asia – Leukemia Statistics, 2018
Figure 12-8: China – Total vs. Active, not Recruiting Leukemia Clinical Trials, 2020
Figure 12-9: Asia – Parameters Contributing to the Current Leukemia Therapeutics Market Status
Figure 13-1: Global - Leukemia Drug Clinical Pipeline by Phase(%), 2019 till 2025
Figure 13-2: Global - Leukemia Drug Clinical Pipeline by Phase(Number of Drugs), 2019 till 2025
Figure 13-3: Global - Leukemia Drug Clinical Pipeline by Country(Number of Drugs), 2019 till 2025
Figure 13-4: Global - Leukemia Drug Clinical Pipeline by Drug Class (Number of Drugs), 2019 till 2025
Figure 13-5: Global - Leukemia Drug Clinical Pipeline by Company/Clinic (Number of Drugs), 2019 till 2025
Figure 13-6: Global - Leukemia Drug Clinical Pipeline by Patient segment (Number of Drugs), 2019 till 2025
Figure 14-1: Vidaza – FDA & First generic Approval Year
Figure 14-2: Vidaza – Branded v/s Generic Price for 100mg Intravenous powder (US$), May’2020
Figure 14-3: Vidaza – Dose for Initial & Subsequent Treatment Cycle (mg/m2)
Figure 14-4: Vidaza – Cost of Initial & Subsequent Treatment Cycle (US$), May’2020
Figure 14-5: Venetoclax - Patent Issue & Expiration year
Figure 14-6: Venetoclax – Price for Various Supplies of 10mg Tablet (US$), June’2020
Figure 14-7: Venetoclax – Price for Various Supplies of 50mg Tablet (US$), June’2020
Figure 14-8: Venetoclax – Price for Various Supplies of 50mg Tablet (US$), June’2020
Figure 14-9: Venetoclax – Price for 42 Kit & Price per unit Kit (US$), June’2020
Figure 14-10: Venetoclax Monotherapy – Recommended Dose by Treatment Week for CLL Management (mg/day), June’2020
Figure 14-11: Venetoclax Combinational – Recommended Dose in Initial & Subsequent Treatment Cycle for CLL (mg/Cycle), June’2020
Figure 14-12: Venetoclax Monotherapy – Recommended Dose for AML (mg/day), May’2020
Figure 14-13: Venclexta – Annual Sales Value (US$ Million), 2017 - 2019
Figure 14-14: Venclexta - Annual Sales Value by Region (US$ Million), 2019
Figure 14-15: Venclexta – Annual Sales Value by Region (%), 2019
Figure 14-16: Global - Venclexta Quarterly Sales Value (US$ Million), 2019
Figure 14-17: Idhifa – Patent Issue & Expiration Year
Figure 14-18: Idhifa – Price for 30 Tablets & Price per unit of Oral Tablet (US$), June’2020
Figure 14-19: Idhifa – Daily & Full Treatment Cost (US$), June’2020
Figure 14-20: Idhifa – Annual Sales Value (US$ Million), 2017 & 2018
Figure 14-21: Idhifa – US v/s Rest of World Annual Sales Value (US$ Million), 2019
Figure 14-22: Idhifa – US v/s Rest of World Annual Sales Value (%), 2019
Figure 14-23: Idhifa – Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 14-24: Vesanoid – FDA Approval & First Generic Approval Year
Figure 14-25: Tretinoin – price for 30 Capsule Supply 7 Price per Unit Capsule (US$), May’2020
Figure 14-26: Tretinoin – price for 100 Capsule Supply & Price per Unit Capsule (US$), May’2020
Figure 14-27: Tretinoin – Minimum & Maximum Treatment Cost (US$), June’2020
Figure 14-28: Ceplene – Europe Market Authorisation & Orphan Designation Year
Figure 14-29: Ceplene – Cost of Single Administration, Single Day Treatment & One Treatment Cycle (US$/GBP), June’2020
Figure 14-30: Trisenox – FDA Approval Year by Strength
Figure 14-31: Trisenox – FDA Approval & First Generic Approval Year
Figure 14-32: Arsenic Trioxide – Price for 100ml Supply & Price per ml of Branded & Generic Intravenous Solution of 1mg/ml Dose, June’2020
Figure 14-33: Arsenic Trioxide – Price for 60ml Supply & Price per ml of Branded & Generic Intravenous Solution of 2mg/ml Dose (US$), June’2020
Figure 14-34: Arsenic Trioxide – Duration of Induction & Consolidation Treatment Cycle (Days)
Figure 14-35: Arsenic Trioxide – Number of Required Induction & Consolidation Treatment Cycle
Figure 14-36: Amnolake – PMDA Approval & Patent Expiration Year
Figure 14-37: Amsacrine – Minimum & Maximum Recommended Dose (mg/m2)
Figure 14-38: Immune Globulin – FDA Approval Year by Brand Name
Figure 14-39: Cuvitru – Price for 1 & 5 ml Supply of 20% Solution (US$), June’2020
Figure 14-40: Cuvitru – Price for 1 & 10 ml Supply of 20% Solution (US$), June’2020
Figure 14-41: Cuvitru – Price for 1 & 20 ml Supply of 20% Solution (US$), June’2020
Figure 14-42: Cuvitru – Price for 1 & 40 ml Supply of 20% Solution (US$), June’2020
Figure 14-43: Cuvitru – Price for 1 & 50 ml of 20% Solution (US$), June’2020
Figure 14-44: Gammagard S/D – Price for 5gm and 10gm Powder for Injection (US$), June’2020
Figure 14-45: Gammagard Liquid – Price for Various Supplies of Solution (US$), June’2020
Figure 14-46: Hyqvia – Price for Various Supplies of Subcutaneous Solution (US$), June’2020
Figure 14-47: Immuno Globulin – Minimum & Maximum Duration of Treatment Cycle (Weeks)
Figure 14-48: Erwinase – Price for Supply of 5 Powders & Price per unit of 10,000 IU Powder for Injection (US$), June’2020
Figure 14-49: Erwinase – Average Cost of Single Administration & Full Treatment Cost (US$), June’2020
Figure 14-50: Global - Erwinase Annual sales Value (US$ Million), 2017 - 2019
Figure 14-51: Global - Erwinase Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 14-52: Oncaspar – FDA & EMA Approval Year
Figure 14-53: Oncaspar – US & Europe Exclusivity Expiration Year
Figure 14-54: Oncaspar – Price for 5 ml Supply & Price per ml of Injectable Solution (US$), June’2020
Figure 14-55: Oncaspar – Recommended Dose by Age (IU/m2 once in 2 Weeks)
Figure 14-56: Asparlas – Price for 1 & 5 mL Solution of Dose 750 units/mL (US$), June’2020
Figure 14-57: Oncaspar – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$)
Figure 14-58: Leunase – Price for 10000IU & 5000IU Powder for Injection (INR/US$), June’2020
Figure 14-59: Leunase – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$)
Figure 15-1: Xospata – Patent Issue Expiration Year
Figure 15-2: Xospata – Price for 30 Tablets & Price per unit Tablet (US$), May’2020
Figure 15-3: Xospata – Daily, Monthly & Annual Treatment Cost (US$), May’2020
Figure 15-4: Global - Xospata Quarterly Sales Value (JPY/US$ Million), 2018 & 2019
Figure 16-1: Bosulif – Patent Issue & Expiration Year
Figure 16-2: Bosulif – Price for 120 Tablet & Price per Unit of 100mg Tablet (US$), June’2020
Figure 16-3: Bosulif – Price for 30 Tablet & Price per Unit of 400 & 500mg Tablet (US$), June’2020
Figure 16-4: Bosulif – Recommended Dose for Newly Diagnosed & Therapy Resisted CML (mg)
Figure 16-5: Sprycel – FDA Approval Year by Tablet Strength
Figure 16-6: Sprycel – Patent Issue & Expiration Year
Figure 16-7: Sprycel – Price for 60 Tablets & Price per Unit Tablet of 20mg, 50mg and 70mg (US$), June’2020
Figure 16-8: Sprycel – Price for 30 Tablets & Price per Unit Tablet of 80mg, 100mg and 140mg (US$), June’2020
Figure 16-9: Sprycel – Recommended Dose by Indication (mg/day)
Figure 16-10: Sprycel – Recommended Pediatric Dose by Weight (mg/day)
Figure 16-11: Iclusig – FDA Approval Year by Tablet Strength (US$), June’2020
Figure 16-12: Iclusig - Patent Issue & Expiration Year
Figure 16-13: Iclusig – Price for 30 tablets & Price per unit Tablet of 15mg & 45mg (US$), June’2020
Figure 16-14: Iclusig – Recommended Initial & Reduced Dose (mg/day)
Figure 16-15: Iclusig – Global Sales Value (US$ Million), 2018 & 2019
Figure 16-16: Global - Iclusig Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 16-17: Tasigna – FDA Approval Year by Indication
Figure 16-18: Tasigna – Patent Issue & Expiration Year
Figure 16-19: Tasigna – Price for 120 Capsules & Price per unit Capsule of 50mg (US$), June’2020
Figure 16-20: Tasigna – Price for 28 & 112 Capsules & Price per unit Capsule of 100 & 200 mg (US$), June’2020
Figure 16-21: Tasigna – Recommended Dose by Indication (mg Twice Daily), June’2020
Figure 16-22: Tasigna – Recommended Pediatric Dose by Surface Area (mg Twice Daily), May’2020
Figure 16-23: Vanflyta– Recommended Dose for AML Treatment (mg/day)
Figure 16-24: Vanflyta– Recommended Dose & Dose after Reduction (mg/day)
Figure 16-25: Supect – Daily, Monthly & Annual Treatment Cost (US$), June’2020
Figure 16-26: Gleevec – FDA Approval by Dosage Form
Figure 16-27: Gleevec – FDA Approval by Indication
Figure 16-28: Gleevec – Patent Issue & Expiration Year
Figure 16-29: Imatinib – Price for 30 Tablet supply of Branded & Generic Imatinib 400mg (US$), June’2020
Figure 16-30: Imatinib – Price for 90 Tablet supply of Branded & Generic Imatinib 400mg (US$), June’2020
Figure 16-31: Gleevec – Recommended Dose by Indication (mg/Day)
Figure 17-1: Vyxeos – FDA Approval & Patent Expiration Year
Figure 17-2: Vyxeos – Price for 1, 2 & 5 Powder for Injection (US$), June’2020
Figure 17-3: Vyxeos – Number of Drug Administration Required in Different Treatment Cycles (Dose/Cycle), June’2020
Figure 17-4: Tibsovo – FDA Approval Year by Indication
Figure 17-5: Tibsovo – Patent Issue & Expiration Year
Figure 17-6: Tibsovo – Price for 60 Tablets & Price per unit of 250mg Tablet (US$), May’2020
Figure 17-7: Tibsovo – Cost of Daily Treatment & Full Treatment Cost (US$), May’2020
Figure 17-8: Global – Tibsovo Sales Value (US$ Million), 2018 & 2019
Figure 17-9: Global – Tibsovo Quarterly Sales Value (US$ Million), 2019
Figure 17-10: Rituxan Hycela – FDA Approval & Patent Expiration Year
Figure 17-11: Rituxan Hycela – Price for 11.7 ml Supply & Price per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US$), February’2020
Figure 17-12: Rituxan Hycela – Price for 13.4 ml Supply & Price per ml of 26,800 units–1,600 mg/13.4ml Subcutaneous Solution (US$), February’2020
Figure 17-13: Rituxan Hycela – Duration of CLL Treatment (Weeks), June’2020
Figure 17-14: Rituxan Hycela - Cost of Single Treatment Cycle & Full Treatment of CLL (US$), June’2020
Figure 18-1: Cladribine – FDA Approval Year by Brand Name
Figure 18-2: Mavenclad – Merck’s Patent Issue & Expiration Year
Figure 18-3: Mavenclad – Ares Trading’s Patent Issue & Expiration Year
Figure 18-4: Mavenclad – Price for various Tablet Supplies of 10mg (US$), June’2020
Figure 18-5: Generic Cladribine – Price for 10 & 1ml Intravenous Solution (US$), June’2020
Figure 18-6: Cladribine – Recommended Dose by Route of Administration (mg/Kg/day)
Figure 18-7: Clolar – FDA Approval & First Generic Approval Year
Figure 18-8: Clolar – Price for 20ml Supply & Price per ml of Intravenous Solution (US$), June’2020
Figure 18-9: Generic Clofarabine – Price for 20ml Supply & Price per ml of Intravenous Solution (US$), May’2020
Figure 18-10: Clolar – Recommended dose & Dose after Reduction (mg/m2/day)
Figure 18-11: Purixan – FDA Approval & Exclusivity Expiration Year
Figure 18-12: Purixan – Price for 100ml Supply & Price per ml of Oral Suspension (US$), June’2020
Figure 18-13: Purixan – Minimum & Maximum Recommended Dose (mg/Kg)
Figure 18-14: Xatmep – Patent Issue & Expiration Year
Figure 18-15: Xatmep – Price for 60ml Supply & Price per ml of Oral Solution (US$), June’2020
Figure 18-16: Xatmep – Price for 100ml Supply & Price per ml of Oral Solution (US$), June’2020
Figure 18-17: Xatmep – Cost of Single Treatment Cycle & Annual Treatment Cost (US$), June’2020
Figure 18-18: Decogen – FDA Approval & first Generic Approval Year
Figure 18-19: Decitabine – Price for 50mg Branded & Generic Intravenous Powder (US$), June’2020
Figure 18-20: Decitabine – Cost of Single Dose, Single day & Single Treatment Cycle using 15mg/m2/Thrice a Day Dose regimen (US$), June’2020
Figure 18-21: Decitabine – Cost of Single Day & Single Treatment Cycle using 20mg/m2/Daily Dose regimen (US$), June’2020
Figure 18-22: Arranon – FDA Approval Year & Patent Expiration Year
Figure 18-23: Arranon – Price for 50ml & 300ml intravenous Solution of 5mg/ml Dose (US$), June’2020
Figure 18-24: Arranon – Adult & Pediatric Dose (mg/m2)
Figure 18-25: Fludarabin – FDA Approval Year by Brand Name
Figure 18-26: Fludarabin – Price for 50mg Intravenous Powder & 2 ml Intravenous Solution for Injection (US$), May’2020
Figure 18-27: Methotrexate – Average Price of 10 ml Supply & Price per ml of 25mg/ml Intravenous Solution (US$), June’2020
Figure 18-28: Methotrexate – Average Price of Different Supplies of Oral Tablet (US$), June’2020
Figure 18-29: Methotrexate – Minimum & Maximum Duration of Initial Treatment Phase of ALL (Weeks), June’2020
Figure 18-30: Methotrexate – Single Treatment Cycle Cost in Initial & Maintenance Phase (US$), June’2020
Figure 18-31: Methotrexate – Minimum & Maximum Treatment Cost of Initial Phase of ALL (US$), June’2020
Figure 18-32: Methotrexate – Duration of Treatment & Rest Period for Choriocarcinoma Treatment (Days), June’2020
Figure 18-33: Methotrexate – Minimum & Maximum Treatment Cost of Single Day (US$), June’2020
Figure 18-34: Methotrexate – Minimum & Maximum Cost of Single Treatment Cycle (US$), June’2020
Figure 19-1: Nipent – FDA Approval & First Generic Approval Year
Figure 19-2: Pentostatin – Price for Single Vial of Generic & Branded Pentostatin (US$), May’2020
Figure 19-3: Mitoxantron – FDA Approval & First Generic Approval Year
Figure 19-4: Mitoxantron – Price for 10ml, 12.5ml & 15 ml Supply of 2mg/ml Intravenous Solution (US$), June 2020
Figure 19-5: Mitoxantron – Minimum & Maximum Dose for Prostate Cancer (mg/3weeks)
Figure 19-6: Idarubicin - FDA & First Generic Approval Year
Figure 19-7: Idarubicine – Price Comparision of 5ml Intravenous Branded & Generic Solution (US$), June’2020
Figure 19-8: Idarubicine – Price Comparision of 10ml Intravenous Branded & Generic Solution (US$), June’2020
Figure 19-9: Idarubicine – Price Comparision of 20ml Intravenous Branded & Generic Solution (US$), June’2020
Figure 19-10: Idarubicin – Dialy & Maximum Cumulative Lifetime Dose (mg/m2), January’2020
Figure 19-11: Idarubicin – Comparision of Dialy & Full Treatment Cost uisng Branded & Generic Tablet (US$), January’2020
Figure 20-1: Copiktra – Interllikine’s Patent Issue & Expiration Year
Figure 20-2: Copiktra – Infinity Pharma’s Patent Issue & Expiration Year
Figure 20-3: Copiktra – Price for 56 Capsules Supply & Price per unit Capsule (US$), June’2020
Figure 20-4: Copiktra – Recommended & Reduced Dose (mg/day)
Figure 20-5: Zydelig – Number of Patents by Assignee
Figure 20-6: Zydelig – Patent Expiration Year by Assignee
Figure 20-7: Zydelig – Price for 60 Tablet Supply & Price per Unit Tablet (US$), June’2020
Figure 20-8: Zydelig – Recommended & Reduced Dose (mg/day)
Figure 20-9: Global - Zydelig Sales Value (US$ Million), 2017 - 2019
Figure 20-10: Zydelig – Annual Sales Value by Region (US$ Million), 2019
Figure 20-11: Zydelig – Annual Sales Value by Region (%), 2019
Figure 20-12: Zydelig – Quarterly Sales Value (US$ Million), 2018 - 2019
Figure 21-1: Bendamustine – FDA Approval Year by Brand Name
Figure 21-2: Treanda – Patent Issue & Expiration Year
Figure 21-3: Bendeka – Number of Patent by Assignee
Figure 21-4: Bendeka – Patent Expiration Year by Assignee
Figure 21-5: Bendamustine – FDA & First Generic Approval Year
Figure 21-6: Bendamustine – Price for 4 ml Supply & Price per ml of Intravenous Solution (US$), June’2020
Figure 21-7: Bendeka – Price for 4 ml Supply & Price per ml of Intravenous Solution (US$), June’2020
Figure 21-8: Belrapzo – Price for 4 ml Supply & Price per ml of Intravenous Solution (US$), June’2020
Figure 21-9: Bendamustine – Comparision of Treatment Cost of CLL uisng Branded & Generic Solution (US$), June’2020
Figure 21-10: Cyclophosphamide – FDA Approval Year by Companies
Figure 21-11: Cyclophosphamide – Average Price for 1gm, 2gm & 500mg Powder for Injection (US$), June’2020
Figure 21-12: Cyclophosphamide – Average Price for a Supply of 100 Capsules of 25mg & 50 mg Dose (US$), June’2020
Figure 21-13: Hikma’s Cyclophosphamide – Average Price for a Supply of 100 Capsules of 25mg Dose (US$), June’2020
Figure 21-14: Cyclophosphamide IV Solution – Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US$), June’2020
Figure 21-15: Cyclophosphamide Capsule – Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US$), June’2020
Figure 22-1: Ibrutinib – FDA Approval Year by Indication
Figure 22-2: Ibrutinib – FDA Approval Year by Dosage Form
Figure 22-3: Imbruvica – Price for 90 & 120 Capsule Supplies of 140mg (US$), June’2020
Figure 22-4: Imbruvica Capsule – Price for 28 Capsule & Price Per unit Capsule of 70mg (US$), June’2020
Figure 22-5: Imbruvica Tablet – Price for 28 Tablets & Price Per unit Tablet of Various Doses (US$), June’2020
Figure 22-6: Imbruvica – Recommended Daily Dose by Indication (mg), May’2020
Figure 22-7: Imbruvica – Annual Sales Value (US$ Billion), 2017 - 2019
Figure 22-8: Imbruvica - Annual Sales Value by Region (US$ Million), 2019
Figure 22-9: Imbruvica – Annual Sales Value by Region (%), 2019
Figure 22-10: Global - Imbruvica Quarterly Sales Value (US$ Million), 2019
Figure 23-1: Besponsa – Orphan Market Exclusivity Issue & Expiration Year
Figure 23-2: Besponsa – Duration of Initial Treatment Cycle & Subsequent Cycles (Days), June’2020
Figure 23-3; Besponsa – Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m2), June’2020
Figure 23-4: Besponsa – Cost of Single Unit & Full Cost of Initial Treatment Cycle (US$), June’2020
Figure 23-5: Besponsa – Cost of Single Unit & Full Cost of Subsequent Treatment Cycle in Patient with CR (US$), June’2020
Figure 23-6: Besponsa – Duration of Treatment of ALL – After & Without HSCT (Weeks), June’2020
Figure 23-7: Mylotarg – FDA Approval, Withdrawal & Re-Approval Year
Figure 23-8: Mylotarg – Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
Figure 23-9: Mylotarg – Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), June’2020
Figure 23-10: Mylotarg – Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML, June’2020
Figure 23-11: Mylotarg – Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days), June’2020
Figure 23-12: Mylotarg – Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2), June’2020
Figure 23-13: Mylotarg – Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US$), June’2020
Figure 23-14: Mylotarg – Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, June’2020
Figure 23-15: Arzerra – Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), June’2020
Figure 23-16: Arzerra – Price for a Supply of 50 ml & Price per ml of Intravenous Solution (US$), June’2020
Figure 23-17: Arzerra – Initial & Maintenance Dose for Previously Untreated CLL (mg), June’2020
Figure 23-18: Arzerra – Minimum & Maximum Treatment Duration for Previously Untreated CLL (Weeks), June’2020
Figure 23-19: Arzerra – Minimum & Maximum Treatment Cost for Previously Untreated CLL (US$), June’2020
Figure 23-20: Arzerra – Initial & Maintenance Dose for Relapsed CLL (mg), June’2020
Figure 23-21: Arzerra – Minimum & Maximum Treatment Cost for Relapsed CLL (US$), June’2020
Figure 23-22: Arzerra – Initial & Maintenance Dose for Refractory CLL (mg), June’2020
Figure 23-23: Arzerra – Treatment Duration for Refractory CLL (Weeks), June’2020
Figure 23-24: Arzerra – Minimum & Maximum Treatment Cost for Refractory CLL (US$), June’2020
Figure 23-25: Gazyva – Approval Year by Non-Hodgkin’s Lymphoma Type
Figure 23-26: Gazyva – Price for 40ml Supply & Price per ml of Intravenous Solution (US$), June’2020
Figure 23-27: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg), June’2020
Figure 23-28: Gazyva – Duration of Single Treatment Cycle & Full Treatment of CLL (Week), June’2020
Figure 23-29: Gazyva – Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US$), June’2020
Figure 23-30: Gazyva – Annual Sales Value (US$/CHF Million), 2016 - 2019
Figure 23-31: Global - Gazyva Quarterly Sales Value (US$/CHF Million), 2018
Figure 23-32: Global - Gazyva Quarterly Sales Value (US$/CHF Million), 2019
Figure 23-33: US - Gazyva Quarterly Sales Value (US$ Million), 2019
Figure 23-34: Gazyva – Annual Sales Value by Region (CHF/US$ Million), 2019
Figure 23-35: Gazyva – Annual Sales Value by Region (%), 2019
Figure 23-36: Gazyva – FDA Approval Year by Indication
Figure 23-37: Rituxan – Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$), June’2020
Figure 23-38: Rituxan – Price for a Supply of 50 ml & Price per ml of Solution for Injection (US$), June’2020
Figure 23-39: Rituxan – Price for a Supply of 100 ml & Price per ml of Solution for Injection (US$), June’2020
Figure 23-40: Rituxan – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-41: Rituxan – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-42: Rituxan – Annual Sales Value (US$/CHF Billion), 2017 - 2019
Figure 23-43: Global - Rituxan Quarterly Sales Value (US$ Billion), 2018 & 2019
Figure 23-44: US - Rituxan Quarterly Sales Value (US$/CHF Billion), 2019
Figure 23-45: Rituxan – Annual Sales Share of US & Rest of World (%), 2019
Figure 23-46: Rituxan – Annual Sales Value by Region (CHF/US$ Billion)), 2019
Figure 23-47: Rituxan – Annual Sales Value by Region (%), 2019
Figure 23-48: Blincyto – Recommended Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, June’2020
Figure 23-49: Blincyto – Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days), June’2020
Figure 23-50: Blincyto – Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US$), June’2020
Figure 23-51: Blincyto – Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, June’2020
Figure 23-52: Blincyto – Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), June’2020
Figure 23-53: Blincyto – Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), June’2020
Figure 23-54: Blincyto – Cost of Different Treatment Phases & Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), June’2020
Figure 23-55: Global - Blincyto Sales Value (US$ Million), 2016 - 2019
Figure 23-56: Blincyto - Sales Value by Region (US$ Million), 2019
Figure 23-57: Blincyto - Sales Value by Region (%), 2019
Figure 23-58: Blincyto – Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 23-59: Lumoxiti – Year of Orphan Designation, FDA Approval & Patent Expiration
Figure 23-60: Lumoxiti – Duration of Single Treatment Cycle & Full Treatment (Weeks), June’2020
Figure 23-61: Lumoxitin – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), June’2020
Figure 23-62: Poteligeo – FDA Approval & Patent Expiration Year
Figure 23-63: Poteligeo – Price for 5ml Supply & Price per unit of 4mg/ml Intravenous Solution (US$), June’2020
Figure 23-64: Poteligeo – Number of Dose Administration in Initial & Subsequent Treatment Cycle
Figure 23-65: Poteligeo – Cost of Single Dose, Initial & Subsequent Treatment Cycle (US$), June’2020
Figure 23-66: Japan - Poteligeo Sales Value (US$ Million), 2018 & 2019
Figure 23-67: Global - Poteligeo Sales Value (US$ Million), 2018 & 2019
Figure 23-68: Japan – Poteligeo Quarterly Sales Value (JPY/US$ Million), 2019
Figure 23-69: ROW – Poteligeo Quarterly Sales Value (JPY/US$ Million), 2019
Figure 23-70: Truxima – Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$), June’2020
Figure 23-71: Truxima – Price for a Supply of 50 ml & Price per ml of Solution for Injection (US$), June’2020
Figure 23-72: Truxima – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-73: Truxima – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-74: Ruxience – Price for 1 & 10 mL Solution of Dose 10 mg/mL (US$), June’2020
Figure 23-75: Ruxience – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-76: Ruxience – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-77: Rixathon – Price for Supply of 2 Vials & Price per unit Vial of 10ml Solution (GBP/US$), June’2020
Figure 23-78: Rixathon – Price for Supply of 2 Vials & Price per unit Vial of 50ml Solution (GBP/US$), June’2020
Figure 23-79: Rixathon – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-80: Ruxience – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-81: Acellbia – Price for Supply of 2 Vials & Price per unit Vial of 10ml Solution (INR/US$), June’2020
Figure 23-82: Acellbia – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-83: Acellbia – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-84: Maball – Price for Supply of 10ml & Price per ml of Injection (INR/US$), June’2020
Figure 23-85: Maball – Price for Supply of 50ml & Price per ml of Injection (INR/US$), June’2020
Figure 23-86: Acellbia – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-87: Acellbia – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-88: Mabtus – Price for Supply of 10ml & Price per ml of Injection (INR/US$), June’2020
Figure 23-89: Mabtus – Price for Supply of 50ml & Price per ml of Injection (INR/US$), June’2020
Figure 23-90: Mabtus – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-91: Mabtus – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-92: Zytux – Price for Supply of 2 Vail & Price per unit Vial of 10ml solution for Injection (LL/US$), June’2020
Figure 23-93: Zytux – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-94: Zytux – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-95: Campath – FDA Approval Year by Brand Name
Figure 23-96: Campath – Cost of Single Dose & Single Treatment Cycle (US$), June’2020
Figure 24-1: Kymriah – FDA approval Year by Cancer Type
Figure 24-2: Kymriah – Number of Patents in US, Europe & Japan
Figure 24-3: Kymriah – Cost of Acute Lymphoblastic Leukemia Treatment (US$ 000’), June’2020
Figure 24-4: Kymriah - Sales Value (US$ Million), 2017 - 2019
Figure 24-5: Kymriah – Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 24-6: Synribo – Patent Issue & Expiration Year
Figure 24-7: Synribo – Treatment Phase in Induction & Maintenance Cycle (Weeks/Cycle)
Figure 24-8: Zalmoxis – Orphan Drug Designation & European Approval Year
Figure 24-9: Zalmoxis – Cost of Single Treatment Cycle & Full Treatment (EUR/US$), June’2020
Figure 25-1: Marqibo – FDA Approval & Patent Expiration Year
Figure 25-2: Marqibo – Recommended Dose & Dose after Reduction (mg/m2 Once Weekly)
Figure 26-1: Intron A – Price for a Supply of 10, 18 & 50 Million IU Powder for Injection (US$), June’2020
Figure 26-2: Intron A – Price for a Supply of 6 & 10 Million IU/ml Intravenous Solution (US$), June’2020
Figure 26-3: Intron A – Average Cost of Single Treatment Cycle for Hairy Cell Leukemia by Dosage Forms (US$), June’2020
Figure 26-4: Intron A – Average Cost of Full Treatment of Course Hairy Cell Leukemia by Dosage Forms (US$), June’2020
Figure 26-5: Roferon-A – Price for a Supply of 3 Million IU & 4.5 Million IU Syringe (INR/US$), June’2020
Figure 26-6: Roferon-A – Recommended Dose by Type of Leukemia (Million IU/ Day)
Figure 29-1: Drivers for Leukemia Therapeutics Market Growth